Zealand Pharma AS (ZLDPF)
(Delayed Data from OTC)
$126.00 USD
0.00 (0.00%)
Updated Aug 28, 2024 12:24 PM ET
2-Buy of 5 2
F Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZLDPF 126.00 0.00(0.00%)
Will ZLDPF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ZLDPF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZLDPF
Here's Why Momentum in Zealand Pharma AS (ZLDPF) Should Keep going
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
ZLDPF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Clearside Biomedical, Inc. (CLSD) Reports Q2 Loss, Lags Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Here's What Could Help Zealand Pharma AS (ZLDPF) Maintain Its Recent Price Strength
Other News for ZLDPF
Zealand Pharma management to meet with Cantor Fitzgerald
Altimmune: Emerging Position In Competitive Space, But Risks Remain
Weight loss drug developers slump as Eli Lilly slashes cost of some Zepbound doses
Eli Lilly, Novo Nordisk to maintain 'two horse race' in GLP-1 weight loss market
International Small-Cap ETF Reaches 52-Week High, Leaving Investors Wondering What's Next